Appropriate Use Criteria (AUC)

Appropriate Use Criteria (AUC) are statements that contain indications describing when, and how often, an intervention should be performed under the auspices of scientific evidence, clinical judgment, and patient values while avoiding unnecessary provisions of services. SNMMI follows a balanced multidisciplinary approach to guidance development by including various stakeholders in the development process. To view the development process, please click the following link: SNMMI AUC Development Process.

Click here to get answers to your reimbursement questions regarding Appropriate Use Criteria. 

Comments or Questions?

The SNMMI Guidance Oversight Committee is continually developing new Appropriate Use Criteria (AUC) and reviewing and updating existing AUC. If you have specific comments or questions on the content of any of the AUC, or if you have suggestions for new AUC that you feel should be written, please contact the SNMMI Guidance Oversight Committee at All comments will be considered in the AUC development process.



Date Approved

Last Update

Document Title

September 15, 2021

March 24,2022

Prostate-Specific Membrane Antigen (PSMA) PET Imaging

• Click here for a printer friendly Fact Sheet version

Video: Primary Author Dr. Hossein Jadvar discusses AUC development process

March 15, 2021 Musculoskeletal Infection Imaging (submitted to JNM in March)
March 29, 2020 PET Myocardial Perfusion Imaging (MPI)
September 27, 2019  

Imaging Evaluation of Biochemical Recurrence of Prostate Cancer Following Definitive Primary Treatment
Click here for a printer friendly Fact Sheet version

September 27, 2019  

Nuclear Medicine in Evaluation and Treatment of Differentiated Thyroid Cancer

September 27, 2019 

Gastrointestinal Transit
Click here for a printer friendly Fact Sheet version

September 9, 2017 October 2020

Somatostatin Receptor PET Imaging in Neuroendocrine Tumors
Click here for a printer friendly Fact Sheet version

June 9, 2017 August 2020

FDG PET/CT Restaging and Response Assessment of Malignant Disease

June 5, 2017 August 2020

Hepatobiliary Scintigraphy in Abdominal Pain

January 20, 2017 August 2020

Ventilation/Perfusion (V/Q) Imaging in Pulmonary Embolism
Click here for a printer friendly Fact Sheet version

January 20, 2017 August 2020

Bone Scintigraphy in Prostate and Breast Cancer
Click here for a printer friendly Fact Sheet version

January 28, 2013  

Amyloid Imaging

Currently Under Development

Brain Imaging (including Amyloid and Tau)

Fever of Unknown Origin (FUO)

18F-FES PET Imaging


177Lu-PSMA Radiopharmaceutical Therapy

Molecular Breast Imaging 

PET for Initial Staging of Neoplastic Disease

To Be Developed

Brain Imaging with HMPO and DAT

Benign Tumors of Thyroid

Radium 223

Renal Imaging


Please let us know if you have any suggestions for future topics for AUC development, or any feedback on the existing publications by contacting us at

Available for Public Comment

As part of the development process, the SNMMI Guidance Oversight Committee will seek public comment on draft documents in order to ensure we are creating the most accurate guidelines. To submit comments on an AUC, please complete the response form and submit to Below are AUC for which we are currently seeking public input:

Comments Due By


Document Title

 September 28, 2022

   Appropriate Use Criteria for Estrogen Receptor (ER)-Targeted PET Imaging with 16α-18F-Fluoro-17β-Fluoroestradiol (18F-FES)